

Blood samples were obtained from 11 human volunteers at 20 minutes, 1 hour and 3 hours following instillation in the eye of 2 drops of ophthalmic solution containing 1 mg trimethoprim and 10,000 units polymyxin B per mL. Peak serum concentrations were approximately 0.03 mcg/mL trimethoprim and 1 unit/mL polymyxin B.

Microbiology: *In vitro* studies have demonstrated that the anti-infective components of Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution are active against the following bacterial pathogens that are capable of causing external infections of the eye:

Trimethoprim: *Staphylococcus aureus* and *Staphylococcus epidermidis*, *Streptococcus pyogenes*, *Streptococcus faecalis*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Haemophilus aegyptius*, *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis* (indole-negative), *Proteus vulgaris* (indole-positive), *Enterobacter aerogenes*, and *Serratia marcescens*.

Polymyxin B: *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter aerogenes* and *Haemophilus influenzae*.

INDICATIONS AND USAGE

Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms:

Staphylococcus aureus, *Staphylococcus epidermidis*, *Streptococcus pneumoniae*, *Streptococcus viridans*, *Haemophilus influenzae* and *Pseudomonas aeruginosa*.*

*Efficacy for this organism in this organ system was studied in fewer than 10 infections.

CONTRAINDICATIONS

Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

NOT FOR INJECTION INTO THE EYE. If a sensitivity reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution occurs, discontinue use. Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is not indicated for the prophylaxis or treatment of ophthalmic neonatorum.

PRECAUTIONS

General: As with other antimicrobial preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.

Information for Patients: Avoid contaminating the applicator tip with material from the eye, fingers, or other source. This precaution is necessary if the sterility of the drops is to be maintained.

If redness, irritation, swelling or pain persists or increases, discontinue use immediately and contact your physician.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis: Long-term studies in animals to evaluate carcinogenic potential have not been conducted with polymyxin B sulfate or trimethoprim.

Mutagenesis: Trimethoprim was demonstrated to be non-mutagenic in the Ames assay. In studies at two

laboratories no chromosomal damage was detected in cultured Chinese hamster ovary cells at concentrations approximately 500 times human plasma levels after oral administration; at concentrations approximately 1000 times human plasma levels after oral administration in these same cells a low level of chromosomal damage was induced at one of the laboratories. Studies to evaluate mutagenic potential have not been conducted with polymyxin B sulfate.

Impairment of Fertility: Polymyxin B sulfate has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.

No adverse effects on fertility or general reproductive performance were observed in rats given trimethoprim in oral dosages as high as 70 mg/kg/day for males and 14 mg/kg/day for females.

Pregnancy: Teratogenic Effects

Pregnancy Category C. Animal reproduction studies have not been conducted with polymyxin B sulfate. It is not known whether polymyxin B sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Trimethoprim has been shown to be teratogenic in the rat when given in oral doses 40 times the human dose. In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with oral doses 6 times the human therapeutic dose.

While there are no large well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell, in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or oral trimethoprim in combination with sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim and sulfamethoxazole. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral trimethoprim and sulfamethoxazole at the time of conception or shortly thereafter. Because trimethoprim may interfere with folic acid metabolism, trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects: The oral administration of trimethoprim to rats at a dose of 70 mg/kg/day commencing with the last third of gestation and continuing through parturition and lactation caused no deleterious effects on gestation or pup growth and survival.

Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 months have not been established (see WARNINGS).

ADVERSE REACTIONS

The most frequent adverse reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash.

Photosensitivity has been reported in patients taking oral trimethoprim.

DOSAGE AND ADMINISTRATION

Adults: In mild to moderate infections, instill one drop in the affected eye(s) every three hours (maximum of 6 doses per day) for a period of 7 to 10 days.

Pediatric Use: Clinical studies have shown Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution to be safe and effective for use in pediatric patients over two months of age. The dosage regimen is the same as for adults.

HOW SUPPLIED

Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is supplied as a sterile solution in plastic dropper bottles in the following size: 10 mL in a 10 mL bottle NDC 17478-703-11

STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.

WARNING – KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

Akorn

Manufactured by: Akorn, Inc.
Lake Forest, IL 60045

ATP00N
Rev. 08/19

Principal Display Panel Text for Container Label:

NDC 17478-703-11

Polymyxin B Sulfate
and Trimethoprim

Ophthalmic Solution

10 mL

For the eye

Sterile

Rx only

The image shows a rectangular label with rounded corners and a red border. On the left side, there are two vertical columns of text: 'EXP.' and 'LOT'. Below these is a barcode with the number '(01)00317478703112' printed vertically to its left. The main body of the label contains the following text:

Each mL contains: Actives: Trimethoprim Sulfate equivalent to Trimethoprim 1 mg (0.1%) and Polymyxin B Sulfate 10,000 units. **Preservative:** Benzalkonium Chloride 0.04 mg (0.004%). **Inactives:** Sodium Chloride, Sulfuric Acid and Sodium Hydroxide may be added to adjust pH (3.0 to 5.5), and Water for Injection.

WARNING - KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

NDC 17478-703-11

**Polymyxin B Sulfate
and Trimethoprim
Ophthalmic Solution**

10 mL

For the Eye

Sterile
Rx only

FOR TOPICAL OPHTHALMIC USE ONLY.
Usual Dosage: One drop in the eye(s) every three hours. See package insert for dosage information.
Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Protect from light.

Akorn, Inc. Lake Forest, IL 60045
ATPAGL Rev. 08/19

Principal Display Panel Text for Carton Label:

NDC 17478-703-11

Polymyxin B

Sulfate and

Trimethoprim

Ophthalmic
Solution
For the eye
10 mL
Sterile
Rx only [Akorn Logo]



POLYMYXIN B SULFATE AND TRIMETHOPRIM

polymyxin b sulfate and trimethoprim solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:17478-703
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
Trimethoprim sulfate (UNII: E377MF8EQ8) (Trimethoprim - UNII:AN164J8Y0X)	Trimethoprim	1 mg in 1 mL
Polymyxin B sulfate (UNII: 19371312D4) (Polymyxin B - UNII:J2VZ07J96K)	Polymyxin B	10000 [USP'U] in 1 mL

Inactive Ingredients

Ingredient Name	Strength
benzalkonium chloride (UNII: F5UM2KM3W7)	
sodium chloride (UNII: 451W47IQ8X)	
sulfuric acid (UNII: O40UQP6WCF)	
sodium hydroxide (UNII: 55X04QC32I)	
water (UNII: 059QF0K00R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:17478-703-11	1 in 1 CARTON	12/17/1998	
1		10 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA065006	12/17/1998	

Labeler - Akorn, Inc. (117696770)

Registrant - Akorn Operating Company LLC (117693100)

Establishment

Name	Address	ID/FEI	Business Operations
Akorn, Inc.		117696832	MANUFACTURE(17478-703) , ANALYSIS(17478-703)

Establishment

Name	Address	ID/FEI	Business Operations
------	---------	--------	---------------------

Akorn, Inc.	117696840	MANUFACTURE(17478-703) , ANALYSIS(17478-703) , PACK(17478-703) , LABEL(17478-703) , STERILIZE(17478-703)
----------------	-----------	---

Revised: 10/2020

Akorn, Inc.